Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03773562 · ClinicalTrials.gov registry record · Phase 4
Imaging the Migraine Brain Pre- and Post-Erenumab
A Phase 4 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 4
- Development phase
- 50
- Enrollment target
NCT03773562: Completed Phase 4 study, sponsored by Mayo Clinic.
NCT03773562 is a Phase 4 study that has completed, run by Mayo Clinic. The registered enrollment target is 50 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03773562, a Phase 4 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 50 participants
- Enrollment target
Study Summary
Researchers are trying to determine if there is a difference between brain images of subjects that do respond to treatment with erenumab and subjects who do not respond to treatment with erenumab using Magnetic Resonance Imaging (MRI).
Interventions
- DRUG Erenumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2019-03-25 |
| Est. Completion | 2022-06-30 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03773562
The ClinicalTrials.gov registry entry for NCT03773562 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Erenumab is the first listed.
NCT03773562 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03773562 about?
NCT03773562 is a clinical study titled "Imaging the Migraine Brain Pre- and Post-Erenumab". Researchers are trying to determine if there is a difference between brain images of subjects that do respond to treatment with erenumab and subjects who do not respond to treatment with erenumab using Magnetic Resonance Imaging (MRI).
What is the current status of trial NCT03773562?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 50 participants. The study started on 2019-03-25. Estimated completion is 2022-06-30.
What interventions are being tested in trial NCT03773562?
The interventions under investigation include: Erenumab (DRUG).
Who is sponsoring clinical trial NCT03773562?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.